Hospital Specialty Availability: Week 52, 1 & 2 Status Report

france is actively addressing ongoing medication shortages, with recent actions including ample fines for pharmaceutical companies and a renewed focus on domestic production. Between December 19, 2025, and January 6, 2026, the national Agency for the Safety of Medicines and Health Products (ANSM) reported disruptions and updated availability data for several hospital-exclusive medications [[1]].

Fluorouracil Pfizer: Availability Update (January 6, 2026)

FLUOROURACIL PFIZER 50 mg/mL concentrate for solution for infusion (fluorouracil) is experiencing availability challenges.

availability Status According to ANSM

[Further details regarding Fluorouracil Pfizer availability were not provided in the source material.]

Lenalidomide Mylan: Availability Schedule

LENALIDOMIDE MYLAN 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, and 25 mg capsules (lénalidomide) are subject to a phased delivery schedule.

Availability Status According to ANSM

• Deliveries of 5 mg, 10 mg, and 20 mg dosages are expected by the end of Febuary 2026.
• The 15 mg dosage has been available as mid-November 2025.
• The 25 mg dosage has been available since the end of November 2025.
• The 2.5 mg and 7.5 mg dosages have been available since the end of December 2025.

Paclitaxel AHCL: Availability Postponed to 2026

PACLITAXEL AHCL 6 mg/mL, concentrate for solution for infusion (paclitaxel) is facing delays.

Availability Status According to ANSM

Availability has been postponed to 2026. [Further details were not provided in the source material.]

Wilfactin: A Colombian emergency Specialty

WILFACTIN 100 IU/mL powder/solvent for solution for injection (human Von Willebrand factor) remains in short supply.

Availability Status According to ANSM

• Hospital Situation: Tension persists.
• Exceptional and transitional provision of Wilfactin 1000 IU/10 mL, lyophilized powder to reconstitute into injectable solution, originally intended for the Colombian market, is in place.
• WILFACTIN is currently reserved for patients undergoing long-term prophylaxis.

Additional Information from the Laboratory

According to a newsletter from the LFB laboratory (October 14, 2025), the manufactured batch complies with French marketing authorization requirements for WILFACTIN 100 IU/mL.

However,the imported batch:

• Is labeled “Export” on the delivery slip and includes an item code.
• Is not serialized.
• Has only two traceability labels (on the bottle) instead of the required three. healthcare professionals are asked to manually document traceability information.